Literature DB >> 28635949

Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis.

Andrea Iorio1, Antonella De Lillo1, Flavio De Angelis1, Marco Di Girolamo2, Marco Luigetti3,4,5, Mario Sabatelli6, Luca Pradotto7, Alessandro Mauro7,8, Anna Mazzeo9, Claudia Stancanelli10, Federico Perfetto11, Sabrina Frusconi12, Filomena My13, Dario Manfellotto2, Maria Fuciarelli1, Renato Polimanti14,15.   

Abstract

Coding mutations in TTR gene cause a rare hereditary form of systemic amyloidosis, which has a complex genotype-phenotype correlation. We investigated the role of non-coding variants in regulating TTR gene expression and consequently amyloidosis symptoms. We evaluated the genotype-phenotype correlation considering the clinical information of 129 Italian patients with TTR amyloidosis. Then, we conducted a re-sequencing of TTR gene to investigate how non-coding variants affect TTR expression and, consequently, phenotypic presentation in carriers of amyloidogenic mutations. Polygenic scores for genetically determined TTR expression were constructed using data from our re-sequencing analysis and the GTEx (Genotype-Tissue Expression) project. We confirmed a strong phenotypic heterogeneity across coding mutations causing TTR amyloidosis. Considering the effects of non-coding variants on TTR expression, we identified three patient clusters with specific expression patterns associated with certain phenotypic presentations, including late onset, autonomic neurological involvement, and gastrointestinal symptoms. This study provides novel data regarding the role of non-coding variation and the gene expression profiles in patients affected by TTR amyloidosis, also putting forth an approach that could be used to investigate the mechanisms at the basis of the genotype-phenotype correlation of the disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28635949      PMCID: PMC5558178          DOI: 10.1038/ejhg.2017.95

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  39 in total

1.  Transthyretin-related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset.

Authors:  Massimo Russo; Anna Mazzeo; Claudia Stancanelli; Rita Di Leo; Luca Gentile; Gianluca Di Bella; Fabio Minutoli; Sergio Baldari; Giuseppe Vita
Journal:  J Peripher Nerv Syst       Date:  2012-12       Impact factor: 3.494

2.  TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?

Authors:  Bernard Bonaïti; Malin Olsson; Urban Hellman; Ole Suhr; Catherine Bonaïti-Pellié; Violaine Planté-Bordeneuve
Journal:  Eur J Hum Genet       Date:  2010-03-17       Impact factor: 4.246

3.  Integrative approaches for large-scale transcriptome-wide association studies.

Authors:  Alexander Gusev; Arthur Ko; Huwenbo Shi; Gaurav Bhatia; Wonil Chung; Brenda W J H Penninx; Rick Jansen; Eco J C de Geus; Dorret I Boomsma; Fred A Wright; Patrick F Sullivan; Elina Nikkola; Marcus Alvarez; Mete Civelek; Aldons J Lusis; Terho Lehtimäki; Emma Raitoharju; Mika Kähönen; Ilkka Seppälä; Olli T Raitakari; Johanna Kuusisto; Markku Laakso; Alkes L Price; Päivi Pajukanta; Bogdan Pasaniuc
Journal:  Nat Genet       Date:  2016-02-08       Impact factor: 38.330

4.  Schwann cells contribute to neurodegeneration in transthyretin amyloidosis.

Authors:  Tatsufumi Murakami; Kazunori Sango; Kazuhiko Watabe; Naoko Niimi; Shizuka Takaku; Zhenghua Li; Ken-ichi Yamamura; Yoshihide Sunada
Journal:  J Neurochem       Date:  2015-03-02       Impact factor: 5.372

5.  In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis.

Authors:  Renato Polimanti; Marco Di Girolamo; Dario Manfellotto; Maria Fuciarelli
Journal:  Amyloid       Date:  2014-04-29       Impact factor: 7.141

6.  Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M).

Authors:  Diana Santos; Teresa Coelho; Miguel Alves-Ferreira; Jorge Sequeiros; Denisa Mendonça; Isabel Alonso; Carolina Lemos; Alda Sousa
Journal:  Eur J Hum Genet       Date:  2015-08-19       Impact factor: 4.246

7.  Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met.

Authors:  Efthimios Dardiotis; Pantelitsa Koutsou; Eleni Zamba-Papanicolaou; Ilia Vonta; Marilena Hadjivassiliou; Georgios Hadjigeorgiou; Marios Cariolou; Kyproula Christodoulou; Theodoros Kyriakides
Journal:  J Neurol Sci       Date:  2009-06-03       Impact factor: 3.181

8.  Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden.

Authors:  Miguel Luz Soares; Teresa Coelho; Alda Sousa; Gösta Holmgren; Maria João Saraiva; Daniel L Kastner; Joel N Buxbaum
Journal:  Eur J Hum Genet       Date:  2004-03       Impact factor: 4.246

Review 9.  Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.

Authors:  Teresa Coelho; Giampaolo Merlini; Christine E Bulawa; James A Fleming; Daniel P Judge; Jeffery W Kelly; Mathew S Maurer; Violaine Planté-Bordeneuve; Richard Labaudinière; Rajiv Mundayat; Steve Riley; Ilise Lombardo; Pedro Huertas
Journal:  Neurol Ther       Date:  2016-02-19

10.  Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis.

Authors:  Andrea Iorio; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Luca G Pradotto; Anna Mazzeo; Sabrina Frusconi; Filomena My; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  BMC Genomics       Date:  2017-03-23       Impact factor: 3.969

View more
  8 in total

Review 1.  Genetic Infiltrative Cardiomyopathies.

Authors:  Mary E Sweet; Luisa Mestroni; Matthew R G Taylor
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179

2.  Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis.

Authors:  Jignesh K Patel; Andrew M Rosen; Adam Chamberlin; Benjamin Feldmann; Christian Antolik; Heather Zimmermann; Tami Johnston; Arvind Narayana
Journal:  Neurol Ther       Date:  2022-08-06

3.  The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression.

Authors:  Gita A Pathak; Antonella De Lillo; Frank R Wendt; Flavio De Angelis; Dora Koller; Brenda Cabrera Mendoza; Daniel Jacoby; Edward J Miller; Joel N Buxbaum; Renato Polimanti
Journal:  Amyloid       Date:  2021-12-22       Impact factor: 6.571

Review 4.  Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.

Authors:  Laura Obici; Roberta Mussinelli
Journal:  Neurotherapeutics       Date:  2021-11-30       Impact factor: 6.088

Review 5.  Transthyretin familial amyloid polyneuropathy: an update.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2017-12-16       Impact factor: 4.849

6.  Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses.

Authors:  Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Hum Genet       Date:  2019-10-29       Impact factor: 4.132

7.  Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms.

Authors:  Gita A Pathak; Frank R Wendt; Antonella De Lillo; Yaira Z Nunez; Aranyak Goswami; Flavio De Angelis; Maria Fuciarelli; Henry R Kranzler; Joel Gelernter; Renato Polimanti
Journal:  Circ Genom Precis Med       Date:  2021-01-11

8.  Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis.

Authors:  Antonella De Lillo; Gita A Pathak; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Federico Perfetto; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Clin Epigenetics       Date:  2020-11-17       Impact factor: 6.551

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.